Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey.

1992 ◽  
Vol 74 (5) ◽  
pp. 1135-1139
Author(s):  
L E Braverman ◽  
B M Pratt ◽  
S Ebner ◽  
C Longcope
2020 ◽  
Vol 6 (5) ◽  
pp. e279-e281
Author(s):  
Jessica Watari ◽  
Navinder Jassil

Objective: We present a patient with long standing hypothyroidism who developed hyperthyroidism secondary to Graves disease. Recognition of this disease phenomenon is crucial to ensure prompt diagnosis and close follow-up. Methods: The patient was evaluated with thyroid function testing and thyroid antibody testing. Further evaluation included ophthalmologic examination and radioactive iodine uptake imaging. Results: A 56-year-old female with past medical history of human immunodeficiency virus, hepatitis C infection, and hypothyroidism presented for evaluation of thyroid disease. She had been off of levothyroxine for the last 8 months due to biochemical findings of thyrotoxicosis. Her family history was significant for hyperthyroidism and hypothyroidism. Laboratory tests were consistent with hypothyroidism so levothyroxine was restarted. Physical exam showed lid lag and proptosis. Ophthalmologic evaluation found bilateral 23 mm proptosis. Additional lab testing was positive for thyroid peroxidase antibody and thyroid stimulating immunoglobulin. Following levothyroxine use, the patient developed subclinical hyperthyroidism and thyroid replacement was stopped. The patient remained euthyroid for 1 year off of levothyroxine. Following 1 year, she developed mild hyperthyroidism with increased radioactive iodine uptake. She was placed on propranolol for symptomatic relief. Months later, thyroid function testing normalized. Conclusion: In Graves disease, hypothyroidism and conversion of hypothyroidism to hyperthyroidism are rare, yet important to recognize, clinical phenomenon. The stimulatory and inhibitory properties of thyroid-stimulating hormone receptor antibodies are speculated to play a role in individuals with alternating hypothyroidism and hyperthyroidism. These individuals can present a diagnostic and therapeutic challenge. Clinicians must maintain a high clinical suspicion for this disease entity.


1990 ◽  
Vol 122 (1) ◽  
pp. 107-114 ◽  
Author(s):  
Ken Okamura ◽  
Kaori Sato ◽  
Mototaka Yoshinari ◽  
Hiroshi Ikenoue ◽  
Takeo Kuroda ◽  
...  

Abstract The prognosis of atrophic hypothyroidism with blocking type TSH-binding inhibitor immunoglobulin was studied. Among 45 patients (16 males and 29 females) with overt hypothyroidism (serum TSH >40 mU/l) without goitre, thyroid autoantibody to microsomal antigen was positive in 38 or 84.4%, and 4 or 8.9% had TSH-binding inhibitor immunoglobulin, which was shown to be a TSH-stimulation blocking antibody by cAMP production assay using cultured porcine thyroid cells. Thyroidal radioactive iodine uptake was low and thyroid hormone replacement therapy was required. Long-term follow up of 2 patients with strongly positive TSH-binding inhibitor immunoglobulin for 2 to 7 years, however, revealed recovery of the thyroid function after steroid therapy or spontaneously with iodide restriction, respectively, correlating with decrease in both TSH-binding inhibitor immunoglobulin and TSH-stimulation blocking antibody activities. Thyroidal radioactive iodine uptake became normal and histological examination of the thyroid in one patient revealed well-preserved thyroid follicles with lymphocytic infiltration. Recovery of thyroid function can be expected with a decrease in TSH-binding inhibitor immunoglobulin activity in atrophic hypothyroidism, which is not necessarily the end stage of chronic thyroiditis.


1960 ◽  
Vol XXXIII (IV) ◽  
pp. 584-592 ◽  
Author(s):  
B.-A. Lamberg ◽  
C. A. Hernberg ◽  
Riitta Hakkila

ABSTRACT Treatment with a thyroid preparation was used in 75 cases of non-toxic goitre. In 63 cases there was nodular goitre in 12 diffuse goitre. The observation period varied from 3 to 42 months. The size of the goitre decreased in 50 cases (68 per cent) of which 40 had a nodular goitre and 10 a diffuse goitre. In the 63 cases with a nodular goitre the size of the nodules decreased in 39 cases and the nodules disappeared completely in 2 cases (65 per cent). In 5 cases (7 per cent) there was no change in the size of the thyroid or the nodules. Temporary factitious hyperthyroidism appeared in 7 cases but subsided rapidly after adjustment of the dose. In one case an endogenous hyperthyroidism evidently developed, probably owing to initial latent hyperthyroidism. Treatment of non-toxic goitre with thyroid preparations or hormones is recommended 1) in diffuse goitre, 2) in nodular goitre as a trial and 3) after thyroidectomy for compressive goitre. The value of radioactive iodine uptake or excretion tests for the assessment of the response to treatment and the adjustment of the dose is emphasized.


2021 ◽  
pp. 73-76
Author(s):  
Vasudev Sankhla ◽  
Aman Deep

Thyroid function tests are one of the most common endocrine panels in general practice because a good understanding of when to order them, indications for treatment are important for the optimal treatment of thyroid dysfunction. Thyroid-stimulating hormone (TSH) should be the rst test to be performed on any patient with suspected thyroid dysfunction and in follow-up of individuals on treatment. It is useful as a rst-line test because even small changes in thyroid function are sufcient to cause a signicant increase in TSH secretion. Thyroxine levels may be assessed in a patient with hyperthyroidism, to determine the severity of hyperthyroxinemia. Antithyroid peroxidase measurements should be considered while evaluating patients with subclinical hypothyroidism and can facilitate the identication of autoimmune thyroiditis during the evaluation of nodular thyroid disease. The measurement of TSH receptor antibody must be considered when conrmation of Graves’ disease is needed and radioactive iodine uptake cannot be done.


1982 ◽  
Vol 7 (8) ◽  
pp. 368-369 ◽  
Author(s):  
J ACOSTA ◽  
R CHITKARA ◽  
F KHAN ◽  
V AZUETA ◽  
L SILVER

Sign in / Sign up

Export Citation Format

Share Document